checkAd

     361  0 Kommentare CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110 in Relapsed or Refractory CD19+ B-cell Malignancies - Seite 5

    CRISPR THERAPEUTICS standard character mark and design logo, CTX110, CTX120, and CTX130 are trademarks and registered trademarks of CRISPR Therapeutics AG.  All other trademarks and registered trademarks are the property of their respective owners.

    Investor Contact:
    Susan Kim
    +1-617-307-7503
    susan.kim@crisprtx.com

    Lesen Sie auch

    Media Contact:
    Rachel Eides
    WCG on behalf of CRISPR
    +1-617-337-4167
    reides@wcgworld.com


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 5 von 5

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110 in Relapsed or Refractory CD19+ B-cell Malignancies - Seite 5 -50% (2/4) complete response (CR) rate at three months in the Dose Level 3 (DL3) cohort; both responders remain in CR- -Early evidence of dose-dependent responses with CTX110- -Acceptable safety profile at DL3 or below- -Management to host …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer